Variability of USP Lot P Prednisone Reference Standard Tablets - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Variability of USP Lot P Prednisone Reference Standard Tablets
The authors demonstrate that anecdotal reports of prednisone tablet variability are inaccurate.

Pharmaceutical Technology


Table III: Intra-experiment %CV (Apparatus 2, Study 3, using six analysts)*.
The intent of the USP PVT for nonsolution orally administered drug products is to ensure continuing equivalence between the clinical trial material on which safety and efficacy conclusions were made and the manufactured article following approval. US regulatory approaches do not require postapproval reconsideration of bioequivalence for drug products, barring postapproval change. Thus, reliance on the USP performance test becomes a key, if not the sole, means of ensuring consistency in drug product performance both within and among manufacturers over many years of drug product manufacture.

Table IV: Intra-experiment %CVs, assembly epsilon (Apparatus 2, Study 4, using two analysts)
The dissolution procedure described in Dissolution ‹711› requires an assembly that allows a kinetic measure of drug release over time. Combining effects from the analyst and analytic procedure, the experimental study of drug product dissolution is performed at batch release and also as part of stability studies. The assembly is a complicated mechanical device with many factors that can influence results. In part, the complexity results from the need to provide some sense of surrogacy for the in vivo condition. For this reason, USP emphasizes the importance of a periodic PVT together with careful mechanical calibration to ensure that the combined experimental study yields consistent results. General Chapter ‹711› has been revised, and the term Apparatus Suitability Test has been replaced with the term Performance Verification Test (1). Although USP reference standard tablets have been referred to as calibrators, this is a misnomer. The tablets are not, and cannot, be used for calibration.

Table V: Intra-experiment %CVs from collaborative studies for USP prednisone tablets (Study 5).
The recent FDA draft guidance for industry attributes the current wide acceptance criteria for USP's PVT to the quality of the USP Prednisone RS Tablet (6). The studies summarized here addressed this issue by determining the contribution to variability that may be attributed to the tablets. Across the studies, one notes that the intra-experiment %CV for USP Lot P Prednisone RS Tablets is consistently below 6–9%, sometimes much below (see Tables I and II). Because the tablets remain relatively constant across the studies and laboratories of Study 5, variability in the %CVs probably is due to factors other than the tablets. If the USP laboratory can achieve 4–5% CV with these prednisone tablets, these numbers reflect the variability contribution from the tablets together with the assay because that cannot be separated out.

The original Lot M of the 10-mg USP prednisone tablet was designed to reproduce FDA's National Center for Drug Analysis #2 10-mg prednisone tablets used for dissolution testing in FDA laboratories. It is of some interest then, that FDA reports for its prednisone tablets a residual variability of a magnitude similar to that seen in the USP laboratory for USP prednisone Lot P, namely 4–5% (17).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology,
Click here